Since its inception in 2019, Emollivet has held a license for Lipidor’s IP relating to the animal segment and a royalty agreement has regulated
On
The purchase price has been set on market terms and amounts to
© Modular Finance, source
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.225 SEK | +2.27% | -3.02% | -55.36% |
04-22 | Lipidor AB Postpones the Publication of Annual Report for 2023 | CI |
03-21 | Lipidor AB Announces Approval for Start of Phase III Clinical Trial of Psoriasis Candidate AKP02G2 | CI |
Since its inception in 2019, Emollivet has held a license for Lipidor’s IP relating to the animal segment and a royalty agreement has regulated
On
The purchase price has been set on market terms and amounts to
© Modular Finance, source
1st Jan change | Capi. | |
---|---|---|
-55.36% | 588K | |
+29.63% | 682B | |
+30.35% | 586B | |
-3.75% | 364B | |
+17.50% | 327B | |
+3.31% | 285B | |
+15.53% | 240B | |
+10.16% | 209B | |
-8.14% | 203B | |
+7.41% | 165B |